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Summary
Background Human genome sequencing has transformed our understanding of genomic variation and its relevance 
to health and disease, and is now starting to enter clinical practice for the diagnosis of rare diseases. The question of 
whether and how some categories of genomic ﬁ ndings should be shared with individual research participants is 
currently a topic of international debate, and development of robust analytical workﬂ ows to identify and communicate 
clinically relevant variants is paramount.
Methods The Deciphering Developmental Disorders (DDD) study has developed a UK-wide patient recruitment 
network involving over 180 clinicians across all 24 regional genetics services, and has performed genome-wide 
microarray and whole exome sequencing on children with undiagnosed developmental disorders and their parents. 
After data analysis, pertinent genomic variants were returned to individual research participants via their local clinical 
genetics team.
Findings Around 80 000 genomic variants were identiﬁ ed from exome sequencing and microarray analysis in each 
individual, of which on average 400 were rare and predicted to be protein altering. By focusing only on de novo and 
segregating variants in known developmental disorder genes, we achieved a diagnostic yield of 27% among 
1133 previously investigated yet undiagnosed children with developmental disorders, whilst minimising incidental 
ﬁ ndings. In families with developmentally normal parents, whole exome sequencing of the child and both parents 
resulted in a 10-fold reduction in the number of potential causal variants that needed clinical evaluation compared to 
sequencing only the child. Most diagnostic variants identiﬁ ed in known genes were novel and not present in current 
databases of known disease variation.
Interpretation Implementation of a robust translational genomics workﬂ ow is achievable within a large-scale rare 
disease research study to allow feedback of potentially diagnostic ﬁ ndings to clinicians and research participants. 
Systematic recording of relevant clinical data, curation of a gene–phenotype knowledge base, and development of 
clinical decision support software are needed in addition to automated exclusion of almost all variants, which is 
crucial for scalable prioritisation and review of possible diagnostic variants. However, the resource requirements of 
development and maintenance of a clinical reporting system within a research setting are substantial.
Funding Health Innovation Challenge Fund, a parallel funding partnership between the Wellcome Trust and the UK 
Department of Health.
Copyright © Wright et al. Open Access article distributed under the terms of CC BY. 
Introduction
The increasing use of whole exome and whole genome 
sequencing in both research1,2 and clinical practice3–5 raises 
questions about how to maximise the diagnostic 
usefulness of genomic data and how to share results with 
research participants and patients. Furthermore, it is 
increasingly deemed ethically desirable to return clinically 
useful results to research participants.6 However, return of 
individual genomic results poses major logistical 
challenges. A robust workﬂ ow must be developed to track 
individual samples and datasets, generate high-quality 
genomic data, ﬁ lter out a very large number of probably 
benign variants, prioritise plausibly pathogenic variants, 
and link these ﬁ ndings to individual clinical data for 
interpretation and appropriate clinical follow-up. 
Health-related ﬁ ndings from a human genome could 
potentially include thousands of variants pertaining to 
hundreds of diﬀ erent conditions,7 almost none of which 
provide clinically useful information for a speciﬁ c 
individual.8 A ﬁ rst step toward addressing these challenges 
is to separate potential genomic ﬁ ndings into those that 
are pertinent to a particular disease investigation and 
those that are non-pertinent (or incidental) to that disease. 
Although many commentators have debated the merits of 
returning diﬀ erent classes of ﬁ ndings from large research 
studies and biobanks,6,9,10 none has yet provided a scalable 
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See Online for appendix 1 implementation from patient identiﬁ cation through to a 
conﬁ rmed diagnosis within a research context. Here we 
describe the development and implementation of a 
translational genomics workﬂ ow in a large-scale rare 
disease research study to communicate pertinent ﬁ ndings 
to individual research participants, whilst minimising 
incidental ﬁ ndings.
The Deciphering Developmental Disorders (DDD) 
study11 is a UK-wide collaborative project that seeks to 
facilitate the translation of genomic sequencing 
technologies into the National Health Service (NHS), by 
collecting a set of high-resolution genomic and phenotypic 
data for children with severe undiagnosed developmental 
disorders and their parents. Although whole genome 
microarray analysis has already proven invaluable 
for identiﬁ cation of large pathogenic copy number 
variants (mostly deletions and duplications) in children 
with developmental disorders,12 most children remain 
undiagnosed. In many cases, the condition is caused by 
a de novo mutation that occurs spontaneously in the 
aﬀ ected child somewhere in the genome,13–15 and if there is 
no family history of the condition the genetic basis of the 
diagnosis can be easily overlooked. The recruitment 
criteria for the study are focused on congenital or early 
onset severe phenotypes, and were speciﬁ cally designed to 
maximise the chance of ﬁ nding a highly penetrant 
monogenic cause for the child’s condition. The study was 
established with the dual aim of assisting the translation 
of new high-throughput genomic technologies into 
clinical practice, and elucidating the underlying genetic 
architecture of developmental disorders. Cambridge 
South Research Ethics Committee (REC) approved the 
feedback of potentially causal variants from DDD to the 
patients’ regional genetics centre, whose responsibility it 
is to assess and validate the ﬁ ndings before communicating 
them to the families with appropriate counselling 
regarding recurrence risk, likely prognosis, and potential 
clinical management. The judgment not to feed back 
incidental ﬁ ndings was REC-approved, and the protocol 
and patient information sheets clearly state that “incidental 
ﬁ ndings will not be reported back in the DDD study”. 
Nonetheless, we developed a parallel research study to 
investigate attitudes towards feeding back a broader range 
of genomic results to research participants.16,17
We outline a process to identify and report likely causal 
variants (pertinent ﬁ ndings) in individual patients, and 
summarise the results to date. There are many diﬀ erent 
classes of disease-causing genetic variation, of which 
some are observed infrequently (eg, uniparental disomy, 
in which both copies of a single chromosome are 
inherited from one parent, which occurs in fewer than 
one in 1000 individuals18), whereas others are observed in 
huge numbers (eg, single DNA base changes, of which 
every individual has millions in their genome). Diﬀ erent 
genetic changes need diﬀ erent analysis methods; in 
particular, more numerous forms of genetic variation 
need a scalable automated approach. We describe the 
workﬂ ow we have developed to achieve a scalable 
genome-wide diagnostic analysis, focusing particularly 
on the automated part of a larger workﬂ ow, and we show 
the clinical usefulness of this workﬂ ow using data for 
1133 probands with severe undiagnosed developmental 
disorders as an example.
Methods
Clinical data collection
We developed a workﬂ ow to facilitate patient recruitment, 
sample tracking, data generation, data analysis, variant 
ﬁ ltering, manual curation, and feedback of results 
(ﬁ gure 1; appendix 1). Clinically ascertained undiagnosed 
patients meeting the recruitment criteria (severe 
undiagnosed neurodevelopmental disorder and/or 
congenital anomalies, abnormal growth parameters, 
dysmorphic features, and unusual behavioural pheno-
types) were recruited to the DDD study by their UK NHS 
or Irish Regional Genetics Service, who also recorded 
clinical information and phenotypes using the Human 
Phenotype Ontology (HPO)19 via a secure web portal 
within the DECIPHER database.20 A team of research 
coordinators (typically research nurses and genetic 
counsellors) working in each of the regional services 
provided essential support with informed consent, 
sample collection, and data entry (antenatal and growth 
data, developmental milestones, family history, previous 
genetic testing, etc) with the patient’s phenotype being 
entered by their clinical geneticist. The study has UK 
Research Ethics Committee approval (10/H0305/83, 
granted by the Cambridge South REC, and GEN/284/12 
granted by the Republic of Ireland REC).
For more on the DDD study see 
www.ddduk.org
For the DECIPHER database see 
https://decipher.sanger.ac.uk
Figure 1: Study workﬂ ow
SNV=single nucleotide variant. Indel=insertion or deletion. CNV=copy number variant. UPD=uniparental disomy. 
Patient recruitment
Clinical data
Selective variant
validation
Automated variant
analysis:
 (1) annotation
 (2) ﬁltering
 (3) prioritisation
Phenotypes Family history
Genomic data
SNVs,  indels,  CNVs UPD, mosaicism
Manual review
Reporting
Diagnostic conﬁrmation and families informed
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Genomic assays
Saliva samples from patients and their parents were 
collected (Oragene DNA collection kits, DNA Genotek, 
Kanata, ON, Canada) and DNA extracted 
(QIAsymphony, Qiagen, Venlo, Netherlands); 
blood-derived DNA from the child was also provided by 
the regional genetics laboratories. DNA samples from 
patients and their parents were analysed at the 
Wellcome Trust Sanger Institute with microarray 
analysis (Agilent 2x1M array CGH [Santa Clara, CA, 
USA] and Illumina 800K SNP genotyping [San Diego, 
CA, USA]) to identify copy number variants (CNVs) in 
Figure 2: Variant ﬁ ltering logic for clinical reporting within the study
Genomic variants were ﬁ ltered on the basis of six factors, of which the ﬁ rst ﬁ ve were automated and the ﬁ nal one was done manually: (1) frequency, prevalence of the variant in the general population (MAF 
≤1%); (2) function, most severe predicted functional consequence, such as LOF, deﬁ ned by speciﬁ c sequence ontology terms (transcript ablation, splice donor variant, splice acceptor variant, stop-gained, 
frameshift variant, stop-lost, initiator codon variant, in-frame insertion, in-frame deletion, missense variant, transcript ampliﬁ cation, and coding sequence variant); (3) location, genomic location compared 
with DDG2P of published genes; (4) variant type, genotype (eg, heterozygous or homozygous) and loss or gain for small CNVs (which were only considered when they contained entire genes in which LOF 
or dominant negative mutations had been previously reported, and gains were only considered when they overlapped genes in which increased gene dosage mutations had been previously reported); 
(5) inheritance, aspects of the pipeline that are dependent on inheritance information derived from parental data are shaded; and (6) phenotype, patient phenotype was manually compared against 
published phenotypes for a particular gene. MAF=minor allele frequency. CNV=copy number variant. LOF=loss of function. DDG2P=Developmental Disorders Genotype-to-Phenotype database.
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the child, and exome sequencing (Agilent SureSelect 
55MB Exome Plus with Illumina HiSeq) to investigate 
single nucleotide variants (SNVs), small insertion-
deletions (indels), and CNVs in coding regions of the 
genome (appendix 1). Putative de novo sequence 
variants identiﬁ ed using DeNovoGear21 were validated 
with targeted Sanger sequencing. The population 
prevalence (minor allele frequency) of each variant in 
nearly 15 000 samples from diverse populations was 
recorded, and the eﬀ ect of each genomic variant was 
predicted with the Ensembl Variant Eﬀ ect Predictor 
(VEP version 2.6)22 (appendix 1).
Variant ﬁ ltering
An automated variant ﬁ ltering pipeline was used to 
narrow down the number of putative diagnostic variants 
(ﬁ gure 2). First, common (>1% minor allele frequency) 
and non-functional (not protein-altering) variants were 
ﬁ ltered out. Second, potentially pathogenic variants in 
known disease genes were selected in by comparison 
against an in-house database of genes consistently 
implicated in speciﬁ c developmental disorders, the 
Developmental Disorders Genotype-to-Phenotype data-
base (DDG2P). This database includes more than 
1000 genes that have been consistently implicated in 
speciﬁ c developmental disorders and is updated regularly 
with newly implicated genes (table 1; appendix 1; 
appendix 2). Each gene in DDG2P is associated with a 
speciﬁ c developmental phenotype or syndrome via a 
particular genetic mechanism (autosomal dominant, 
autosomal recessive, or X-linked) and mutation 
consequence on the gene product (loss of function, 
activating mutation, increased gene dosage, etc). The use 
of DDG2P enabled any rare variant in a known DD gene 
with a predictable eﬀ ect on the gene product to be ﬂ agged 
on the basis of inheritance, genotype, and likely 
mutational consequence. Large, rare CNVs overlapping 
non-DDG2P genes were also ﬂ agged based on a series of 
size thresholds (>100 kb for losses and >250 kb for gains 
where the inheritance was either de novo or segregated 
with disease, and >500 kb for any genic CNV for which 
the inheritance was unclear).
Sharing of results
Flagged variants were manually reviewed in a weekly 
multidisciplinary team meeting including clinical 
geneticists and genetic scientists to assess their 
analytical and clinical validity. Patients’ detailed clinical 
presentation and family history were compared against 
published clinical features for each gene containing 
ﬂ agged variants, to evaluate the likely relevance in 
that speciﬁ c patient. When there were suﬃ  ciently 
overlapping clinical features, the variant (chromosome, 
position, gene[s], allele, genotype, inheritance, and 
most severe predicted consequence) was approved for 
reporting to the regional genetics service via the 
patient’s referring clinician. Variants were deposited 
into the patient’s record via the secure study web 
portal DECIPHER, where they could be viewed in an 
interactive genome browser to enable local evaluation, 
diagnostic laboratory validation, and discussion with 
the family as appropriate. Anonymised variants were 
made publicly accessible after a short holding period (to 
ensure the opportunity for families to be informed 
before release). Full genomic datasets were also 
deposited in the European Genome-Phenome Archive 
in accordance with the REC approval for the study.
Role of the funding source
The funders of the study did not contribute to the study 
design, data collection, data analysis, data interpretation, 
report writing, or the decision to submit this paper for 
publication. The corresponding author had full access to 
all the data in the study and ﬁ nal responsibility for the 
decision to submit for publication.
Results
To achieve equity of access for all undiagnosed families 
with developmental disorders in the British Isles, every 
UK NHS regional genetics service was involved 
in supporting and setting up the study; Ireland was 
subsequently added after the study had started. Almost 
all consultant clinical geneticists (more than 180) across 
all 24 regional genetics services in the UK and Ireland 
have recruited families to the DDD study, with the help 
of local research coordinators (typically research nurses 
or genetic counsellors). Around 2000 families were 
recruited in the ﬁ rst year of the study, rising to more 
than 8000 within 3 years. Among the ﬁ rst 1133 complete 
family trios (child, mother, and father), the male-to-female 
ratio among the probands was 51:49 and the median age 
at last clinical assessment was 5·5 years (SD 4·0, range 
0–16). 121 (11%) children had one parent aﬀ ected with a 
(typically milder) developmental phenotype, and 23 (2%) 
had both parents aﬀ ected with developmental phenotypes 
(most often mild intellectual disability). Before entering 
DDD, 868 (77%) of the cohort had received clinical 
microarray testing, 633 (56%) had at least one targeted 
genetic test, and 522 (46%) had received both. Across the 
cohort, 1435 unique phenotype terms of the roughly 
July, 
2012
November, 
2012
July, 
2013
November, 
2013
Total reportable genes* 819 875 1075 1128
Genes added ·· 60 201 60
Genes removed† ·· 4 1 7
 In addition to genes being added or removed, annotations for existing genes can 
also change (eg, to include multiple modes or mechanisms). The November, 2013 
version was used for the analysis presented here and includes 1128 reportable genes. 
DDG2P=Developmental Disorders Genotype-to-Phenotype database. *DDG2P also 
contains non-reportable categories when there is insuﬃ  cient evidence associating a 
gene and developmental disorder (appendix 1). †The selection of variants for 
reporting is based on the strongest available evidence of gene function and no 
variants yet reported have been retracted because of changes in the DDG2P list.
Table 1: Changes to DDG2P over time
See Online for appendix 2
For the European Genome-
Phenome Archive see www.ebi.
ac.uk/ega
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10 000 available in the HPO were used to describe clinical 
presentations, with a mode of 4 per proband (range 1–27); 
987 (87%) children had intellectual disability, 270 (24%) 
had a history of seizures, and 121 (11%) had a congenital 
heart defect (ﬁ gure 3).
Around 80 000 genomic variants were identiﬁ ed from 
exome sequencing and array comparative genomic 
hybridisation in each individual proband, of which on 
average 400 were rare and protein altering, and 
30 of these overlapped known DDG2P genes. Further 
ﬁ ltering based on DDG2P categories resulted in a 
median of 10 ﬂ agged SNVs and indels per proband in 
the absence of parental data (range 2–25). We further 
reﬁ ned this to a median of 1 per proband (range 0–13) 
using inheritance information derived from parental 
data (ﬁ gure 4). The diﬀ erence between the number of 
variants with and without parental data is primarily due 
to heterozygous benign variants in dominant genes 
inherited from unaﬀ ected parents (table 2). Probands 
with unaﬀ ected parents had a mean of 0·9 (SD 0·9) 
variants ﬂ agged, which increased to 3·2 (2·4) with one 
aﬀ ected parent and 7·4 (2·7) with two aﬀ ected parents 
(ﬁ gure 4). In addition to SNVs and indels, a further 
0·2 CNVs per proband were ﬂ agged.
All ﬂ agged variants were automatically annotated with 
pathogenicity scores from two variant prioritisation 
algorithms (SIFT23 and PolyPhen24) and compared against 
the public Human Gene Mutation Database (HGMD) and 
the Leiden Open Variation Database (LOVD), which 
together contained only 14% of ﬂ agged variants. The 
phenotypes recorded for each patient were compared 
against those previously published for patients with 
similar mutations in the same gene, using primarily 
DDG2P, PubMed, GeneReviews, and OMIM. If the 
patient’s phenotype was deemed to be inconsistent with 
the genetic change (on the basis of current knowledge of 
the phenotypic spectrum of that gene), the variant was not 
returned to the patient’s clinician. The manual review is 
the most human-intensive step of the workﬂ ow, but was 
essential for validation and improvement of the automated 
ﬁ ltering and prevention of likely non-pathogenic and 
incidental ﬁ ndings from being reported. We expedited the 
review of the variants in the most frequently observed 
genes by requiring speciﬁ c clinical features (eg, deafness) 
that related to these genes to be noted in the patient. 
Figure 3: Representation of phenotypic diversity in cohort
Our patient cohort represents children with  a wide range of severe undiagnosed 
developmental disorders ascertained clinically across the UK.
Seizures (24%)
Intellectual disability or
developmental delay (87%)
Autism spectrum disorder (10%)
Congenital heart 
defects (11%)
Polydactyly (1%)
Hearing impairment (7%)
Oral cleft (6%)
Visual impairment (3%)
Scoliosis (5%)
Figure 4: Analysis of ﬂ agged variants in all 1133 children excluding (red) and including (blue) ﬁ ltering on the 
basis of parental genotypes and aﬀ ected status (using the November 2013 version of DDG2P)
(A) Histogram of the number of ﬂ agged single nucleotide variants and insertion-deletions in 1133 children with and 
without parental data. (B) Mean number of ﬂ agged variants per child with and without parental data for families where 
neither, one, or both parents are aﬀ ected by a developmental phenotype, subdivided by DDG2P genetic mechanism. 
Note that compound heterozygous variants are counted once. Red=proband-only analysis. Blue=family-trio analysis 
with parental genotype data. Filled=autosomal dominant DDG2P genes. Vertical stripes=autosomal recessive DDG2P 
genes. Horizontal stripes=X-linked DDG2P genes. DDG2P=Developmental Disorders Genotype-to-Phenotype database.
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Recent work has highlighted the need for caution in 
interpretation of X-linked causes of intellectual disability,25 
and we made the decision not to consider any inherited 
missense variants on the X-chromosome (except in 
patients with a family history of developmental disorders 
or when the variant itself was present in either HGMD or 
LOVD) because of the large number of variants but low 
prior probability of causality for this class of variation.
After automated variant ﬁ ltering, we manually reviewed 
1696 candidate variants in 1133 family trios and reported 
317 likely diagnostic SNVs, indels, and CNVs (table 3). 
Many of these diagnostic variants have subsequently 
been validated in an accredited diagnostic laboratory and 
communicated to individual families. Additionally, we 
found six likely pathogenic cases of uniparental disomy26 
and ﬁ ve large mosaic chromosomal rearrangements 
(unpublished data). We reported two separate genetic 
ﬁ ndings in 17 individual cases in which both ﬁ ndings 
might contribute to the phenotype.
With 328 likely diagnostic or strongly contributory 
variants in 311 of 1133 children, our overall diagnostic rate 
is 27%. Within DDG2P genes, de novo variants accounted 
for 65% of our diagnoses across the cohort, and 92% of 
those that were validated were regarded as pathogenic 
(table 3). Although some genes were hit multiple times, 
we found a diagnosis in only 146 (13%) individual DDG2P 
genes, of which 92 were hit only once in this cohort 
(appendix 2). We assessed the performance of ﬁ ve variant 
prioritisation tools23,24,27–29 to help to interpret the 
pathogenicity of missense variants (90% of ﬂ agged 
variants), and found that PolyPhen and MutationTaster 
discriminated equally well between reported and 
non-reportable variants (appendix 1), but were nonetheless 
unable to predict the likely diagnostic variants accurately.
Discussion
We have developed and implemented a scalable workﬂ ow 
within a large-scale rare-disease research study to allow 
return of clinically pertinent genetic variants to clinicians 
and research participants (panel). The workﬂ ow is 
consistent with recently recommended guidelines for 
investigating causality of sequence variants in human 
disease,34,35 and we hope that it will act as a prototype for 
the translation of diagnostic genome sequencing into the 
clinic for a range of rare diseases. The semi-automated 
system we have described achieved a diagnostic yield of 
27% in previously investigated, yet undiagnosed, children 
with developmental disorders caused by variants in 
known genes across the genome (ﬁ gure 5; appendix 1). 
The system is amenable to an iterative approach to 
reanalysis of patient data, and we expect that our 
diagnostic yield will increase in the coming years as a 
result of novel gene discovery (both within36 and outside 
of the DDD study) and ongoing improvements to the 
analysis algorithms and variant ﬁ ltering rules.
De novo variants had by far the highest predictive 
value and diagnostic yield in our cohort, highlighting the 
value of having genotype data from both parents as well 
as the child. Of our 215 likely de novo diagnoses, 41 were 
CNVs and 174 were SNVs or indels, of which around half 
(90/174) were novel missense variants and half (84/174) 
were likely loss-of-function variants. Although we 
attempted to validate almost all putative de novo SNVs 
and indels in our cohort using targeted Sanger 
sequencing—the diagnostic gold standard—this process 
sometimes needed several attempts to optimise primer 
design and achieve high-quality data. Given appropriate 
quality thresholds and read depths in all three family 
members, we believe that trio exome sequencing is 
Family-trio analysis Proband-only analysis
Inherited De novo*
Autosomal dominant 473 193 9529
Autosomal recessive (homozygotes) 83 0 191
Autosomal recessive (compound 
heterozygotes)†
341 6 1071
X-linked dominant 38 21 269
X-linked recessive 322 15 387
Total 1257 235 11 447
Inherited variants in autosomal dominant DDG2P genes account for the main diﬀ erence, in which only de novo variants 
and those inherited from an aﬀ ected parent are likely to be of clinical interest. Around 90% of ﬂ agged variants were 
predicted to be missense point mutations. DDG2P=Developmental Disorders Genotype-to-Phenotype database. 
*Before secondary validation by targeted Sanger sequencing. †Two or more likely pathogenic variants in diﬀ erent copies 
of the same gene, counted once per compound variant.
Table 2: Total number of single nucleotide variants and insertion-deletions ﬂ agged by the clinical 
reporting workﬂ ow in all 1133 probands (in the November, 2013 version of DDG2P) compared with the 
number of variants that would have been ﬂ agged in the same probands in the absence of parental data
Reviewed (SNV, 
CNV)
Reported as 
likely 
diagnostic
Predictive 
value of ﬂ ag 
(%)
Diagnostic yield 
(%; n=1133)
Autosomal dominant
De novo 242 (193, 49) 184 75% 16%
Inherited 528 (473, 55) 27 5% 2%
Autosomal recessive
De novo 6 (6, 0) 0 ·· ··
Inherited 425 (424, 1) 52 13% 5%
X-linked
De novo 41 (36, 5) 31 75% 3%
Inherited 371 (360, 11) 23 6% 2%
Uncertain inheritance 83 (0, 83) 0 ·· ··
Chromosomal events
Uniparental disomy ·· 6 ·· 0·5%
Mosaicism ·· 5 ·· 0·5%
Total 1696 328 19% 27%*
See appendix 2 for details of individual genes and phenotype classes. The predictive value is the probability that a 
ﬂ agged variant was reported as likely diagnostic (reported or reviewed), and the diagnostic yield is the contribution of 
that type of variant to the overall diagnostic yield. Note that three pairs of siblings and two pairs of monozygotic twins 
received the same diagnosis. Only 14% of reported variants were present in the public Human Gene Mutation Database 
or Leiden Open Variation Database; 84% of ﬂ agged variants present in these databases were not reported, because 
they did not appear to be relevant to the child’s phenotype. SNV=single nucleotide variant. CNV=copy number variant. 
*17 probands received two contributory pathogenic variants.
Table 3: Likely diagnoses in the ﬁ rst 1133 families
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highly accurate for assessing de novo mutations, but 
that targeted Sanger validation will remain important for 
diagnostic conﬁ rmation and cascade testing.
For families in which neither parent is aﬀ ected by the 
same disorder, sequencing of parent–child trios rather 
than individual probands oﬀ ers around a ten-times 
reduction in the number of candidate variants, thus 
substantially increasing the speed and likelihood of 
reaching an accurate diagnosis. By contrast, when one or 
both parents are similarly aﬀ ected, trio sequencing oﬀ ers 
only a three-times or 1·5-times reduction, respectively, and 
might therefore be less informative. By contrast with our 
trio-sequencing approach, de novo variants could instead 
be identiﬁ ed in a stepwise fashion by exome sequencing of 
the proband, then assay of possibly pathogenic variants in 
both parents by targeted Sanger sequencing. However, in 
view of the rapidly decreasing cost of exome and genome 
sequencing (currently £1000–5000 per individual genome), 
trio exome sequencing could oﬀ er a more rapid, 
cost-eﬀ ective, and scalable diagnostic method in addition 
to providing increased usefulness in research.
Since most of our cohort had received at least 
one genetic test before entering the study, introduction of 
exome sequencing early in the diagnostic pathway could 
substantially reduce costs and increase diagnostic yields 
versus current clinical practice. Additionally, a small but 
growing number of childhood developmental disorders 
are amenable to existing therapeutic interventions, and 
early treatment oﬀ ers substantial beneﬁ ts in preventing 
irreversible clinical manifestations of the condition. 
Currently, 82 reportable DDG2P genes are associated 
with inborn errors of metabolism, which are causally 
related to intellectual disability, and are potentially 
amenable to therapy.37 To date, ﬁ ve DDD children have a 
diagnostic variant in one of these treatable ID genes 
(DHCR7, IVD, LMBRD1, MTR, and SLC2A1) and might 
be suitable for either dietary restriction, supplementation, 
or pharmacological intervention.
When developing our clinical feedback policy, our aim 
was to maximise likely diagnoses while minimising 
incidental ﬁ ndings, and we were conscious of the fact 
that clinical teams have neither the resources nor the 
remit to attempt to validate multiple variants of uncertain 
signiﬁ cance in every patient. Like any medical test, the 
variant ﬁ ltering process necessitates a trade-oﬀ  between 
sensitivity and speciﬁ city, and any change to the analytical 
pipeline will potentially alter this balance. With an 
ever-expanding set of genes implicated in developmental 
disorders, and in light of the fact that around 80% of our 
ﬂ agged variants did not appear to be relevant to the 
child’s developmental disorder, we hope to use 
the manually curated results presented here to reﬁ ne the 
variant ﬁ ltering rules further. Speciﬁ cally, we expect to be 
able to lower the frequency threshold to 0·1% for 
dominantly inherited variants and, following an analysis 
of variant prioritisation methods (appendix 1), to use 
PolyPhen to exclude low-scoring inherited missense 
variants predicted to be benign. Although we plan to 
automate more of the clinical reporting process, we 
expect that some variants will always need expert 
gene-speciﬁ c clinical and scientiﬁ c interpretation.
Because of the large number of rare variants in every 
genome that are unrelated to disease, a genotype–
phenotype database (such as DDG2P) is crucial to allow 
novel variants to be prioritised on the basis of current 
knowledge of gene–disease associations and allelic 
requirements. In principle this approach could be applied 
to any medical specialism for the diagnosis of highly 
penetrant genetic conditions. Although it is possible to use 
a generic genotype-to-phenotype database for variant 
ﬁ ltering based on a broad phenotype (ie, developmental 
disorders), detailed phenotypes are crucial for assignment 
of likely patho genicity to candidate variants. Fewer 
candidate variants could be ﬂ agged by use of a smaller, 
more targeted list, and restriction of the assay to only this 
list of genes could potentially reduce the cost. We used the 
DDG2P database to allow return of variants when the 
patient’s phenotypes, developmental milestones, and 
morphometric data were consistent with published reports 
(this approach was not intended to allow association of 
new phenotypes with known genes, which will need 
further research). However, the value of whole genome or 
exome sequencing as compared with targeted gene panels 
For more on existing 
therapeutic interventions see 
http://www.treatable-id.org
Panel: Research in context
Systematic review
Trio exome sequencing is a highly successful research tool for new gene discovery.2 A 
recent health technology assessment concluded that there is “scarce evidence supporting 
the use of whole exome sequencing for etiologic diagnosis in patients with ID/DD”, and 
warned that this technology presents “ethical dilemmas related to incidental ﬁ ndings in 
the analysis of genetic material in these patients”.30 A systematic review was not done, 
but we are aware of two smaller studies that have shown the likely usefulness of trio 
exome sequencing for clinical diagnosis of children with severe intellectual disability, 
including 51 patients from Germany or Switzerland31 and 100 patients from Nijmegen 
(Netherlands).5 Clinical investigation of 410 rare disease patients from the University of 
California32 achieved a 31% diagnostic rate for trio-based exome sequencing, and a large 
single-centre study of 2000 rare disease patients from Baylor (USA)33 reported a 
diagnostic rate of 25% using exome sequencing of the proband followed by targeted 
follow-up testing in the parents. 
Interpretation
Deciphering Developmental Disorders (DDD) is the ﬁ rst nationwide exome sequencing 
study. It involves more than 1000 children with undiagnosed developmental disorders and 
their parents, combining genome-wide data from high-resolution microarrays and trio 
exome sequencing to maximise detection of potentially pathogenic variants. It achieved a 
consistent diagnostic rate while demonstrating a scalable, collaborative model for 
translational research. The informatics workﬂ ow developed by DDD has addressed one of 
the key ethical challenges raised by massively parallel sequencing technologies and, by 
using a clinically targeted analysis, shown that incidental ﬁ ndings can be minimised. The 
DDD study will continue to recruit throughout the UK and Ireland until April, 2015, and 
aims to reach 12 000 patients; we expect to continue to improve our analysis workﬂ ow 
and increase the diagnostic rate higher than 30% as novel causal genes are discovered and 
incorporated into diagnostic analyses, allowing existing patient data to be reinterpreted.
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lies primarily in the research potential for gene discovery,36 
and the clinical usefulness of enabling future diagnoses to 
be made in current patients from existing data. This 
diagnostic beneﬁ t is already apparent within our cohort, in 
which, on average, 20 new disease-implicated genes are 
published and added to DDG2P per month, making 
iterative analysis across the entire genomic dataset, 
coupled with automated variant ﬁ ltering and re-reviewing, 
essential to maximise the diagnostic beneﬁ t.
An outstanding question remains regarding whether 
researchers should actively search for so-called incidental 
ﬁ ndings38 and thus undertake genomic screening of 
medically relevant genomic variation as recommended 
in standard clinical practice by the American College 
of Medical Genetics and Genomics.39 We note that 
searching for incidental ﬁ ndings in this manner is a 
choice not a prerequisite of whole-genome sequencing, 
because the analysis can be entirely diagnostically 
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Figure 5: Genetic diagnoses associated with broad phenotype categories
Circos-style plot representing the genetic heterogeneity within developmental disorders, showing individual diagnoses in known Developmental Disorders 
Genotype-to-Phenotype database genes, which links the genomic location of each gene with some key phenotypes in each child. Phenotypes are listed outside the 
widest arc of the circle, chromosome numbers are indicated outside the smaller arc, and individual gene names are listed inside. Links are coloured by phenotype 
group. See appendix 2 for details of the diagnoses. ID=intellectual disability. CHD=congenital heart defect. ASD=autism spectrum disorders. Deaf=hearing 
impairment. Cleft=oral cleft. VI=visual impairment. MC=microcephalic dwarﬁ sm. PD=polydactyly.
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targeted (as we have shown). At the outset of DDD, we 
could not be conﬁ dent that actively screening for 
additional incidental ﬁ ndings unrelated to the child’s 
developmental disorder would be in the best interests of 
the patients and families within DDD, particularly in 
view of the paucity of data regarding the true signiﬁ cance 
of such variants ascertained in individuals with no 
known previous risk of the cognate disease. Additionally, 
such screening could potentially undermine established 
clinical practice with respect to screening of children for 
adult-onset conditions.
Nonetheless, furnished with supplementary 
genotype-to-phenotype databases or speciﬁ c variant 
lists, the analytical procedure we have described could 
be adapted to allow simultaneous opportunistic 
screening for many conditions, if this were deemed to 
be ethically appropriate and evaluation showed that 
there was evidence of beneﬁ t to support this approach.8 
However, the infrastructure needed to create and 
support this workﬂ ow is considerable, and substantial 
investment of staﬀ  time at all levels is needed to 
ensure that it is accurate and robust. Hundreds of 
individuals were involved in data entry, generation, 
management, processing, analysis, interpretation, 
and dissemination within DDD, including around 
15 full-time staﬀ  with a dedicated laboratory and 
priority access to a high-performance computing 
cluster. Around 75 h were spent manually reviewing 
the ﬂ agged variants in meetings that were attended by 
between two and eight people including at least one 
consultant clinical geneticist, and assessing the 
clinical relevance of rare functional variants even in 
well-known developmental disorder genes was often 
very challenging. Interpretation of variants relating to 
many other diseases in the absence of known 
symptoms or family history would be even harder, 
particularly in the absence of robust data concerning 
population-ascertained penetrance, and additional 
disease-speciﬁ c expertise would no doubt be needed. 
For these reasons, we chose to focus on identifying 
pertinent ﬁ ndings within the DDD study to maximise 
diagnostic yield and drive research into the underlying 
causes of developmental disorders.
Contributions
CFW drafted the paper. TWF, WDJ, JFM, MvK, HVF, DRF, MEH, and 
CFW contributed to clinical review meetings. DRF and HVF created and 
maintain DDG2P. JCB, SC, TWF, PJ, DAK, MvK, JFM, KIM, VP, AS, 
and ART developed analysis packages, variant ﬁ ltering algorithms, and 
software to assist reporting. KA, DMB, TB, SG, NK, LEM, EP, and DR 
were responsible for sample processing, DNA extraction, and array 
comparative genomic hybridisation. PJ, MvK, RM, EP, and DR 
undertook capillary sequence validation of de novo variants. APB, EB, 
EAC, HVF, MEH, and GJS are responsible for the DECIPHER database 
that allows recruitment and clinical reporting. AM and MP provided 
ethical advice and contributions to the paper. JCB, NPC, DRF, HVF, 
MEH, MP, and CFW are the management team. HVF is the clinical lead 
and MEH is the scientiﬁ c lead of the DDD study.
Declaration of interests
We declare no competing interests.
Acknowledgments
We thank all the staﬀ  at the regional genetics services in the UK and 
Ireland (listed in appendix), the core sample processing and analysis 
pipelines at the Wellcome Trust Sanger Institute, and the patients and 
families in DDD. The DDD study presents independent research 
commissioned by the Health Innovation Challenge Fund (grant number 
HICF-1009-003), a parallel funding partnership between the Wellcome 
Trust and the Department of Health, and the Wellcome Trust Sanger 
Institute (grant number WT098051). The views expressed in this 
publication are those of the author(s) and not necessarily those of the 
Wellcome Trust or the Department of Health. The research team 
acknowledges the support of the National Institute for Health Research, 
through the Comprehensive Clinical Research Network.
References
 1 Lupski JR, Reid JG, Gonzaga-Jauregui C, et al. Whole-genome 
sequencing in a patient with Charcot-Marie-Tooth neuropathy. 
N Engl J Med 2010; 362: 1181–91.
 2 Bamshad MJ, Ng SB, Bigham AW, et al. Exome sequencing as a tool 
for mendelian disease gene discovery. Nat Rev Genet 2011; 12: 745–55.
 3 Yang Y, Muzny DM, Reid JG, et al. Clinical whole-exome 
sequencing for the diagnosis of mendelian disorders. N Engl J Med 
2013; 369: 1502–11.
 4 Worthey EA, Mayer AN, Syverson GD, et al. Making a deﬁ nitive 
diagnosis: successful clinical application of whole exome 
sequencing in a child with intractable inﬂ ammatory bowel disease. 
Genet Med 2011; 13: 255–62.
 5 de Ligt J, Willemsen MH, van Bon BWM, et al. Diagnostic exome 
sequencing in persons with severe intellectual disability. 
N Engl J Med 2012; 367: 1921–29.
 6 Wolf SM, Crock BN, Van Ness B, et al. Managing incidental ﬁ ndings 
and research results in genomic research involving biobanks and 
archived data sets. Genet Med 2012; 14: 361–84.
 7 Kohane IS, Masys DR, Altman RB. The incidentalome. JAMA 2006; 
296: 212–15.
 8 Wright CF, Middleton A, Burton H, et al. Policy challenges of 
clinical genome sequencing. BMJ 2013; 347: f6845.
 9 Berg JS, Khoury MJ, Evans JP. Deploying whole genome 
sequencing in clinical practice and public health: meeting the 
challenge one bin at a time. Genet Med 2011; 13: 499–504.
 10 Dorschner MO, Amendola LM, Turner EH, et al. Actionable, 
pathogenic incidental ﬁ ndings in 1000 participants’ exomes. 
Am J Hum Genet 2013; 93: 631–40.
 11 Firth HV, Wright CF, the DDD Study. The Deciphering 
Developmental Disorders (DDD) study. Dev Med Child Neurol 2011; 
53: 702–03.
 12 Sagoo GS, Butterworth AS, Sanderson S, Shaw-Smith C, 
Higgins JPT, Burton H. Array CGH in patients with learning 
disability (mental retardation) and congenital anomalies: updated 
systematic review and meta-analysis of 19 studies and 
13 926 subjects. Genet Med 2009; 11: 139–46.
 13 O’Roak BJ, Deriziotis P, Lee C, et al. Exome sequencing in sporadic 
autism spectrum disorders identiﬁ es severe de novo mutations. 
Nat Genet 2011; 43: 585–89.
 14 Vissers LELM, de Ligt J, Gilissen C, et al. A de novo paradigm for 
mental retardation. Nat Genet 2010; 42: 1109–12.
 15 Topper S, Ober C, Das S. Exome sequencing and the genetics of 
intellectual disability. Clin Genet 2011; 80: 117–26.
 16 Middleton A, Parker M, Wright CF, Bragin E, Hurles ME, on behalf 
of the DDD Study. Empirical research on the ethics of genomic 
research. Am J Med Genet A 2013; 161: 2099–101.
17 Middleton A, Morley KI, Bragin E, et al, on behalf of the Decipherin g 
Developmental Disorders Study. No expectation to share incidental 
ﬁ ndings in genomic research. Lancet 2014; published online Dec 17. 
http://dx.doi.org/10.1016/S0140-6736(14)62119-X. 
18 Robinson WP. Mechanisms leading to uniparental disomy and 
their clinical consequences. BioEssays 2000; 22: 452–59.
 19 Robinson PN, Mundlos S. The human phenotype ontology. 
Clin Genet 2010; 77: 525–34.
 20 Bragin E, Chatzimichali EA, Wright CF, et al. DECIPHER: database 
for the interpretation of phenotype-linked plausibly pathogenic 
sequence and copy-number variation. Nucleic Acids Res 2014; 
42 (Database issue): D993–1000.
Articles
1314 www.thelancet.com   Vol 385   April 4, 2015
 21 Ramu A, Noordam MJ, Schwartz RS, et al. DeNovoGear: de novo 
indel and point mutation discovery and phasing. Nat Methods 2013; 
10: 985–87.
22 McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F. 
Deriving the consequences of genomic variants with the Ensembl 
API and SNP eﬀ ect predictor. Bioinformatics 2010; 26: 2069–70.
 23 Kumar P, Henikoﬀ  S, Ng PC. Predicting the eﬀ ects of coding 
non-synonymous variants on protein function using the SIFT 
algorithm. Nat Protoc 2009; 4: 1073–81.
 24 Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for 
predicting damaging missense mutations. Nat Methods 2010; 
7: 248–49.
 25 Piton A, Redin C, Mandel J-L. XLID-causing mutations and 
associated genes challenged in light of data from large-scale human 
exome sequencing. Am J Hum Genet 2013; 93: 368–83.
 26 King DA, Fitzgerald TW, Miller R, et al. A novel method for detecting 
uniparental disomy from trio genotypes identiﬁ es a signiﬁ cant 
excess in children with developmental disorders. Genome Res 2014; 
24: 673–87.
 27 Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. 
A general framework for estimating the relative pathogenicity of 
human genetic variants. Nat Genet 2014; 46: 310–15.
 28 Petrovski S, Wang Q, Heinzen EL, Allen AS, Goldstein DB. Genic 
intolerance to functional variation and the interpretation of 
personal genomes. PLoS Genet 2013; 9: e1003709.
 29 Schwarz JM, Rodelsperger C, Schuelke M, Seelow D. 
MutationTaster evaluates disease-causing potential of sequence 
alterations. Nat Methods 2010; 7: 575–76.
 30 Pichon Riviere A, Augustovski F, Garcia Marti S, et al. Whole 
exome sequencing for patients with intellectual disability/mental 
retardation or ASD. Informe de Respuesta Rápida 320. Buenos 
Aires: Institute for Clinical Eﬀ ectiveness and Health Policy, 2013.
31 Rauch A, Wieczorek D, Graf E, et al. Range of genetic mutations 
associated with severe non-syndromic sporadic intellectual 
disability: an exome sequencing study. Lancet 2012; 380: 1674–82.
32 Lee H, Deignan JL, Dorrani N, et al. Clinical exome sequencing for 
genetic identiﬁ cation of rare mendelian disorders. JAMA 2014; 
312: 1880–87.
33 Yang Y, Muzny DM, Xia F, et al. Molecular ﬁ ndings among patients 
referred for clinical whole-exome sequencing. JAMA 2014; 
312: 1870–79.
34 Koboldt DC, Larson DE, Sullivan LS, et al. Exome-based mapping 
and variant prioritization for inherited mendelian disorders. 
Am J Hum Genet 2014; 94: 373–84.
 35 MacArthur DG, Manolio TA, Dimmock DP, et al. Guidelines for 
investigating causality of sequence variants in human disease. 
Nature 2014; 508: 469–76.
36 DDD Study. Large-scale discovery of novel genetic causes of 
developmental disorders. Nature (in press).
 37 van Karnebeek CDM, Stockler S. Treatable inborn errors of 
metabolism causing intellectual disability: a systematic literature 
review. Mol Genet Metab 2012; 105: 368–81.
 38 Gliwa C, Berkman BE. Do researchers have an obligation to actively 
look for genetic incidental ﬁ ndings? Am J Bioeth 2013; 13: 32–42.
 39 Green RC, Berg JS, Grody WW, et al. ACMG recommendations for 
reporting of incidental ﬁ ndings in clinical exome and genome 
sequencing. Genet Med 2013; 15: 565–74.
